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Abstract
Nowadays, one cannot but recognize a key role of the
peripheral and central glial cells for generation of
clinical neuropathic pain. Many cytokines are released
from glial cells, immune cells and nociceptive primary
afferent central or peripheral terminals by injury,
bacterial or viral infection, and envenomation by bee
venom or scorpion. Released cytokines mutually affect
by paracrine or autocrine manner among glias,
immune cells and neurons, thereby produce and
transmit the exaggerating pain information to the brain.
Indeed, suppression of activated glia and immune
cells by chemical agents or antibodies can relief
abnormal pain caused by various experimental
neuropathies. Thus, abnormal exaggerated pain
cannot be explained without the role of glia and
immune cells. Many investigators emphasized that
therapeutic use of inactivating agents to glial and
immune cells but not to neurons is available for
alleviation of clinical pain. Thermo-TRP channels,
TRPV1, TRPA1 and TRPM8 could not sense
neuropathic pain by themselves without close
interactions between glias, immune cells and TRP
channels. The removal of persistent clinical pain will
be rescued by treatment with inactivating chemicals to
glias and immune cells. In addition, physiological
noxious heat could be sensed by unknown sensor
other than thermo-TRP channels, TRPV1, TRPA1 and
TRPM8
Introduction
Pathological pain (hyperalgesia: acute or persistent
exaggerated pain induced by peripheral or central
nerve injury, allodynia: pain induced by innocuous
touch or thermal stimuli under normal conditions) is
caused by infections, tissue damage, envenomation,
and injury (including experimental neurotomy) to the
peripheral nerves or spinal cord. Peripheral
sensitization involves the activation of peripheral nerve
nociceptors (capsaicin receptor, TRPV1) and glial cells
within dorsal root ganglion (DRG), and a phenotypic
change in primary sensory neurons after intraplantar
injection of algogens (i.e., larger DRG neurons switch
to express substance P (SP) [1] or TRPV1 [2]). On the
other hand, central sensitization involves the activation
of microglia and astrocytes mainly in the spinal
superficial dorsal horn underlying the interaction of
immune cells and intrinsic neurons via cytokines and
neurotransmitters.
Recently, we reported the role of central and
peripheral glia, and thermo-TRP channels (TRPV1,
TRPA1 and TRPM8) in pathological pain [3]. It was
demonstrated that many kinds of cytokines mutually
acting between glias, immune cells and nociceptive
sensory neurons have crucial role in generation of
neuropathic pain after experimental neuropathy. In the
present review, further literature survey was
undertaken to enhance the interaction between glial
cells and sensory neurons in neuropathic pain,
especially focused on the role of glia.
Several Factors Participating
in Neuropathic Pain
Another aspect of sensitization in the superficial dorsal
horn (substantia gelatinosa: SG), anatomical
reorganization in the SG, purinergic (P2X) receptors,
and glial and immune cells are referred as several
factors relevant to the induction of abnormal pain.
Central sensitization also includes the activation of
brain stem inhibitory neurons which descends to the
spinal dorsal horn from the rostral ventromedial
medulla (RVM), and the indirect stimulation of
secondary nociceptive neurons via the inactivation of
inhibitory interneurons (disinhibitory sensitization) [4].
Accordingly, since this descending pathway tonically
facilitates the spinal nociceptors, spinal cord
transection and inactivation of the neurons in the RVM
can reduce central sensitization (pain relief) [4]. Spinal
disinhibition resulting in hyperalgesia was suggested
due to down-regulation of inhibitory neurotransmitters
(GABA or glycine) and their receptors, and the
inhibitory neuronal cell death after constriction injury of
peripheral nerves [5].
Moreover, central sensitization may occur through the
sprouting of large Aβ myelinated fibers into lamina II
(anatomical reorganization) in the spinal dorsal horn
after nerve damage [6-8] or the topical application of
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capsaicin [9]. Thus, progressive tactile hypersensitivity
in inflamed animals was thought to be due to sprouting
of low threshold Aβ fibers which normally do not sense
nociception [10]. Nerve growth factor (NGF)
immunoreactive activation of microglia, a subset of
astrocytes and putative Schwann cells (peripheral
nerve glia) in dorsal entry zones, was demonstrated in
the injured area 1 to 2 weeks after spinal cord
transection [11]. NGF released from these cells was
assumed to promote the sprouting of primary afferents
in the spinal dorsal horn after injury [11]. 
Besides, activation of P2X receptors [a subfamily of
P2 (purinergic) receptor for ATP] expressed in the
nociceptive neurons (P2X3), dorsal horn interneurons
(P2X3) and spinal cord microglia (P2X4) is thought to
contribute to the generation of neuropathic pain after
peripheral nerve injury [12, 13].
Several reviews [14-16] specifically infer how central
and peripheral glia is involved in the induction or
propagation of neuropathic pain (other related reviews
are cited in the reference [3]). The importance of
interactions between immune cells (T-lymphocytes,
macrophages, neutrophils and dendritic cells)
including central glias (microglias and astrocytes) and
peripheral glias (satellite cells and Schwann cells),
endothelium, fibroblasts and mast cells (immune and
inflammatory cells), and central and peripheral
neurons was repeatedly referred by Watkins and
Maier [16]. Glia and immune cells release
inflammatory cytokines (tumor necrosis factor: TNF,
interleukin: IL-1, 6) in response to pathological
conditions [16]. Thus, neuro-immune interactions were
stressed to participate in the development of
peripheral neuropathies [17, 18]. Immune suppressant
such as cyclosporine A is considered to reduce
neuropathic pain [16]. Complex regional pain
syndrome (CRPS) I (reflex sympathetic dystrophy) and
CRPS II (causalgia), mirror image (uninjured side)
pain and extraterritorial pain changes, and clinical
back pain are explained by immune or autoimmune
effects on the peripheral (PNS) and central nervous
system (CNS) [16]. Being confronted with these
mounting evidences, the authors suggested that the
available drugs for clinical pain must target glias but
not neurons [19].
Glial Activation in
Experimental Neuropathy
Spinal dorsal horn glias are now well known to be
activated in response to subcutaneous (s.c.)
inflammation, s.c. yeast cell walls, intraperitoneal (i.p.)
bacteria, peripheral nerve and spinal cord trauma
(neuropathic conditions after nerve constriction or
transection), bone cancer, and immune activation in
the spinal cord, all of which are able to generate
hyperalgesia [20]. Namely, glial activation affects
pathological pain rather than normal acute pain [20].
Activated glia (also mast cells) release IL-1, IL-6 and
TNF and these receptors are expressed in both
neurons and glia [14, 21]. These proinflammatory
cytokines are thought to reinforce pain in the spinal
cord [20].
Watkins et al. [22] studied the effects of several glial
metabolic inhibitors [fluorocitrate (inhibitor of astrocyte
activation), CNI-1493 (tetravalent guanylhydrazone
compound, inhibitor of nitric oxide synthesis and
cytokine), and TNF-bp (binding protein, antagonist of
TNF)] in hyperalgesic conditions after formalin
injections using the rat spinal cord. They found that
fluorocitrate and CNI-1493 but not TNF-bp inhibited
formalin-induced hyperalgesia, suggesting the
participation of glia in the mediation of hyperalgesia.
The role of IL-1, TNFα, and NO produced by glia was
emphasized [22]. Allodynic behavior was closely
associated with an enhancement of the immune
reactivity of complement receptor C3bi (OX42, marker
of microglia), major histocompatibility complex II (OX6,
marker of microglia) and glial fibrillary acidic protein
(GFAP, marker of astroglia) in the superficial dorsal
horn [23].
A neurotrophic virus, HIV-1 can cross the blood- brain
barrier and activate microglia and astrocytes. Microglia
and astrocytes recognize a glycoprotein, gp 120,
expressed on the surface of HIV-1 [24]. Intrathecal
(i.t.) application of gp 120 induced mechanical
allodynia and hyperalgesia. Thus, the importance of
spinal cord microglia and astrocytes to hyperalgesia
and allodynia was stressed [24]. HIV gp120
application into the sciatic nerve up-regulated the TNF
α, suggesting the release from the activated
astrocytes or microglia in the spinal dorsal horn and
DRG [binding of gp120 with CXCR4 on Schwann cells
releases RANTES (regulated upon activation, normal
T-cell expressed, and secreted) or chemokine ligand 5
(CCL5)], followed by leading to TNFα production by
DRG neurons [25].  Furthermore, mechanical allodynia
induced by gp120 application was lost by knockdown
of TNFα with siRNA or recombinant TNFα receptor
[25]. Thus, the role of TNFα by glial and DRG cell
activation was emphasized in the HIV-sensory
neuropathy [25].
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Cytokines, cyclooxygenase (COX) products, and NO
released from activated microglia were suggested as
serious inducers of neuropathic pain [26]. IL-1β
-dependent COX2 induction and PGE2 release were
demonstrated in the CNS of rats injected with
complete Freund’s adjuvant (CFA) into the hind paw
[27].
Tight ligation of the lumbar spinal nerve induced an
increase of fibroblast growth factor (FGF)-2 and FGF-2
mRNA expression in the ipsilateral dorsal horn
astrocytes [26]. The activated astrocytes and increase
of FGF-2 in the dorsal horn paralleled the induction of
mechanical allodynia 2 weeks after surgery,
suggesting that FGF-2 is involved in the central
sensitization after peripheral nerve injury [28]. It was
demonstrated in rats that ipsilateral glial cells
(microglia and astroglia) in the medullary superficial
dorsal horn (MDH, lamina I-II) were activated following
inferior alveolar and mental nerve transection (IMANT)
associated with hyper tactile sensitivity [29]. Since the
number of trigeminal ganglion (TG) neurons did not
show a decrease, the authors concluded that the glial
activation is due to degenerative effects of the TG
neurons but to the release of substances from the
central terminals of the primary afferent neurons.
Minocycline (inhibitor of microglial activation) reduced
pain hypersensitivity after trigeminal nerve transection
in parallel with a decrease in the phosphorylation of
p38 MAP (mitogen activated protein) and microglial
activation [29]. Substances released from nociceptive
central afferent terminals and /or MDH neurons were
presumed to be cause of glial activation (neuronal
effects on central glia) [29].
AV411(ibudilast:3-isobutyryl)1-2-isopropylpyrazole-pyri
dine, inactivation chemicals for glial cells) reduced
mechanical allodynia induced by chronic constriction
injury (CCI) of sciatic nerve and tight spinal nerve
ligation (SNL) in rats [30]. The efficacy of AV 411 was
closely related to the decrease in immunoreactivity for
GFAP in the lumbar spinal dorsal horn on the operated
side [30]. The authors proposed to use AV 411 for the
clinical regulation of chronic pain.
Intraplantar injection of Asian scorpion Butus martensi
Karsch (BmK) into the rat hind paw induced thermal
and bilateral mechanical hyperalgesia and early and
late activation of microglia and astrocyte, respectively,
suggesting the share of microglia and astrocyte in
BmK envenomation-induced pain [31]. From the
available time difference, astrocyte was considered to
contribute the persistence of bilateral mechanical
hyperalgesia. The activation of microglia and
astrocytes in the ipsilateral superficial dorsal horn and
pain-related behavior were reduced by the i.t. injection
of fluorocytrate or i.p. injection of minocycline. The
therapeutic potential of glial inhibition was stressed for
the treatment of patients stung by scorpions [31].
Relationships between
Sensory Neurons and Glia
Upon stimulation with supernatant of damaged
sensory neurons by repeated freezing and thawing
(SDSN), the mRNA expression of TNF-α, IL-1β, IL-6
and inducible nitric oxide synthetase (iNOS) increased
in the wild-type microglia, but almost completely
disappeared in the toll-like receptor 2 (TLR2)
knock-out cells [32]. These results indicate that TLR 2
mediates the effects of nerve injury factors (for
instance, SDSN), leading to mechanical allodynia and
thermal hyperalgesia [32]. Although the chemicals of
SDSN are not known, unknown substances from
damaged neurons were predicted as important
inducers of neuropathic pain. 
Inhibition of glutamate recycling (accumulation of
glutamate) in DRG cells caused by a decrease of
glutamate transporters in the satellite glial cells (SGC)
after nerve injury and activation of macrophages were
emphasized to explain the chronic neuropathy [33].
Thus, the role of SGC in neuropathic pain was
proposed. 
Protein kinase (PKs) sensitizes TRPV1 to agonists
(acid, heat, exogenous or endogenous vanilloids) by
potentiating the channel opening and leads to
activation of primary afferent neurons by inflammatory
mediators (bradykinin, mast cell tryptase and
histamine) [34]. The anatomical and biochemical
interaction between primary afferent nerve terminals
and mast cells (immune and inflammatory cells) is
thought to ensure a key role of TRPV1 in
neuro-immune interaction responsible for neuropathic
pain [34]. 
Release of the chemokine CCL2 [chemokine (c-c motif)
ligand 2] from the central terminals of the nociceptive
primary afferents, predominantly P2X3 expressing
small DRG neurons, activated the microglia which in
turn generated the neuropathic pain behavior [35].
Interaction between DRG neurons and spinal microglia
via CCL2 was suggested in inducing mechanical
allodynia [35]. However, the mechanisms of
neuron-glia communication and of the release of ATP,
glutamate and other chemical mediators from glia
underlying the pathophysiological conditions are yet to
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be defined [36].
As noted above, it is becoming steady evidence that
induction of neuropathic pain is dependent on the
activated glia and interactions between glias and
neurons in the PNS and CNS. However, the acute
physiological noxious heat can be sensed without
TRPV1 channel irrespective of tissue inflammation [3,
37, 38]. In fact, noxious heat was normally sensed
despite the profound loss of capsaicin-sensitive DRG
neurons and inflammation induced by carrageenan in
mice treated with capsaicin on 2 days after birth [39].
Thus, the pathways of transduction for pathological
and physiological noxious heat pain were separately
illustrated in Fig. 1.
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Fig.1. Interrelationships among glial cells, immune cells, and nociceptive primary sensory
neurons (PNS) and secondary sensory neurons in the superficial dorsal horn (CNS).
Various inflammatory mediators [ATP, Bradykinin, CGRP (calcitonin-gene related
peptides), Glutamate, Histamine, IL-6, IL-1β, NGF, NO, Prostanoid, Protease, SP,
TNFα, CCL5 etc.] called inflammatory soup are released from peripheral or central
nociceptive primary afferent terminals, immune cells (dendritic cells, endothelial
cells, T-lymphocytes, mast cells, macrophage, microglia etc.) by environmental or
internal pathophysiological stresses, and mutually influence the activation or
inactivation of the release the substances. Therefore, various kinds of receptors are
concomitantly up-regulated on glias, neurons and immune cells. The signals of
neuropathic (clinical) pain are conducted from injured site to (via nociceptive
neurons; TRPV1, TRPA1 or TRPM channels: peripheral sensitization) to the spinal
dorsal horn where the signals are more potentiated (central sensitization). As a result, 
Illustrations
Illustration 1
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exaggerated pain (hyperalgesia or allodynia) will be produced (pathways indicated by red
arrows). Neither glias and immune cells alone nor TRP thermo-sensors alone can
sense the exaggerated pain. In contrast, the acute physiological noxious heat may be
sensed by an unknown sensor without via TRP thermo-channels, and glial and
immune cells (pathway indicated by yellow arrows).
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